Clinical Trials Logo

Clinical Trial Summary

Low dose hydrocortisone IV in patients with CAP fastens recovery of pneumonia and prevents the development of sepsis related complications with a significant reduction in duration of mechanical ventilation


Clinical Trial Description

Inclusion Criteria Minor criteria includes

- respiratory rate > 30 bpm at admission;

- ratio of PaO2 to fraction of inspired oxygen (PaO2:FIO2 ) < 250;

- chest radiograph showing bilateral involvement or multilobar involvement;

- systolic blood pressure < 90 mm Hg; or

- diastolic blood pressure < 60 mm Hg. Major criteria includes

- Requirement of MV;

- Increase in the size of opacities on chest radiograph of 50% or more at 48 hours;

- Requirement of vasopressors for more than 4 hours; or

- Serum creatinine 2 mg/dl or more.

Exclusion criteria:

- Children;

- Nosocomial pneumonia;

- Hospitalisation within the previous 14 days;

- Severe immunosuppression (chronic use of systemic steroids);

- Non-steroid immunosuppressive treatment or HIV);

- Chronic chest disease; , tuberculosis, aspiration or obstructive pneumonia;

- Congestive heart failure (cerebrovascular stroke);

- Chronic renal or hepatic disease;

- Acute burn injury;

- Malignancy;

- Pregnancy; and

- Major gastrointestinal bleed within 3 months of the current hospitalization

Study Outcome The end-points of the study were improvement in PaO2:FIO2 (PaO2:FIO2 > 300 or ≥100 increase from study entry) and sepsis related organ failure assessment, (SOFA) score by day 8 and the development of delayed septic shock.

The adopted SOFA score (up to 6 points) was proposed by Vincent et al., [21]. The number of MV-free days was defined as the number of days after ventilation was discontinued up to study day 8. Shock was defined as requirement of vasopressors. ARDS was defined by consensus criteria.

All the patients were subjected to

1. Routine laboratory screen, including CBC, RBS, serum urea and creatinine, liver enzymes, serum billirubin and coagulation profiles;

2. Chest X ray on at least on admission and at day 8;

3. ABG at least once daily to detect PaO2:FIO2;

4. CRP daily from day 1 to 8 and

5. Evaluation of SOFA score daily ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01228110
Study type Interventional
Source Cairo University
Contact
Status Completed
Phase N/A

See also
  Status Clinical Trial Phase
Completed NCT02559310 - Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia Phase 3
Completed NCT01530763 - Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP) Phase 2/Phase 3
Completed NCT02517489 - Community-Acquired Pneumonia : Evaluation of Corticosteroids Phase 3
Not yet recruiting NCT01937832 - A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia Phase 3
Completed NCT02454114 - HOME FIRST Pilot: a Study of Early Supported Discharge in Patients With Lower Respiratory Tract Infections N/A
Completed NCT00653172 - Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia Phase 2
Recruiting NCT02139163 - Epidemiological Study on Community Acquired Pneumonia
Completed NCT03411824 - Lung Ultrasound for Community-acquired Pneumonia Diagnosis in Emergency Medicine
Recruiting NCT06210282 - The Effect of Focused Lung Ultrasonography on Antibiotic Prescribing in General Practice N/A
Withdrawn NCT02269644 - A P3 Comparator Trial in Community Acquired Bacterial Pneumonia Phase 3
Recruiting NCT01963442 - Short Duration Treatment of Non-severe Community Acquired Pneumonia Phase 2
Terminated NCT00887276 - Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia Phase 4
Not yet recruiting NCT00390819 - Epidemiology of Community Acquired Pneumonia in North Israel N/A
Completed NCT00079885 - Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia Phase 3
Not yet recruiting NCT04158310 - Evaluation the Clinical Value of Xiyanping Injection in the Treatment of Community-acquired Pneumonia in Children
Recruiting NCT02552342 - Corticosteroid Therapy for Severe Community-Acquired Pneumonia Phase 4
Completed NCT02922387 - Smoking Cessation Intervention in Respiratory Inpatients Phase 4
Completed NCT00467701 - Community Acquired Pneumonia in Telemark and Ostfold N/A
Completed NCT04198571 - Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
Completed NCT02107001 - Lung Ultrasound in Pleuritic Chest Pain N/A